Deutsche Bank Research has kept Novartis at a Buy rating with a price target of 140 Swiss francs, citing positive study data for remibrutinib in relapsing multiple sclerosis.
Analyst Emmanuel Papadakis wrote on Tuesday that the remibrutinib data were clearly positive. The note was first distributed at 07:57 CET on 2 September 2026, although the original study did not specify a publication date or time.
Novartis shares trade under ISIN CH0012005267.
